Loading company…
Belgian clinical-stage biopharmaceutical company developing regenerative tissue products to heal large bone defects.
Novadip Biosciences S.A. develops regenerative tissue products to accelerate healing of large bone defects and injuries, including the allogeneic NVD-X3 product and NVD-003, an autologous therapy for congenital pseudoarthrosis of the tibia. Founded in 2013 by Denis Dufrane and Jean-François Pollet and based in Mont-Saint-Guibert, Belgium, it is a spin-off of Université Catholique de Louvain and St. Luc University Hospital. It received EUR 16 million in grant funding from the Walloon Region of Belgium in November 2022 and is listed at the Series B stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in